MLR 1023

Key Product Details

Product Description

MLR 1023 is a selective allosteric activator of Lyn kinase (EC₅₀ = 63 nM); displays no significant activity against a range of 47 other kinases, including other Src family kinases such as Fyn, Lck and Src kinase. Reduces blood glucose levels without affecting in vivo insulin secretion. Orally bioavailable.

Product Specifications for MLR 1023

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for MLR 1023

The following data is based on the product molecular weight 202.21.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	4.95 mL	24.73 mL	49.45 mL
5 mM	0.99 mL	4.95 mL	9.89 mL
10 mM	0.49 mL	2.47 mL	4.95 mL
50 mM	0.10 mL	0.49 mL	0.99 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 6 publications citing the usage of this product.

• Saporito MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo. J.Pharmacol.Exp.Ther. 2012 PMID: 22473614
• Ochman The Lyn kinase activator MLR-1023 is a novel Ins receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes. J.Pharmacol.Exp.Ther. 2012 PMID: 22431203

Product Documents for MLR 1023